跳至主要内容
临床试验/NCT00865488
NCT00865488暂停3 期

A Prospective, Controlled, Randomized, Multi-Center, Pivotal Study Evaluating the Safety and Efficacy of AdhexilTM in Prevention And/Or Reduction of Adhesions in Gynecology Surgery

OMRIX Biopharmaceuticals5 个研究点 分布在 5 个国家目标入组 80 人开始时间: 2009年5月最近更新:
适应症

试验速览

阶段
3 期
状态
暂停
入组人数
80
试验地点
5
主要终点
Adhesions will be assessed according to incidence, extent and severity.

研究概览

简要总结

The objective of this study is to evaluate the safety and efficacy of ADHEXIL™ in preventing and/or reducing post-operative adhesions in patients undergoing surgery involving the ovaries.

详细描述

Patients will be divided into two arms: 1) patients who will be treated in accordance with standard of care; 2) patients for which ADHEXIL™ will be applied on one ovary and fallopian tube.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Female patients aged 18-45 years at screening.
  • Patients undergoing elective laparoscopic surgery involving at least one adnexa.

排除标准

  • Pregnant (including ectopic pregnancy) or breastfeeding patient.
  • Patients with a documented diagnosis of cancer.
  • Patients with a lymphatic, hematologic or coagulation disorder.
  • Patients with a known or suspected hypersensitivity to blood, blood products or any constituent of Adhexil™.
  • Patients who are immunocompromised, possess autoimmune disorders, or who are routinely taking anticoagulants.
  • Patients who have participated in another clinical study within 30 days of enrolment.
  • Investigator's opinion that the patient is medically unfit or would be at major risk if enrolled into the study.

结局指标

主要结局

Adhesions will be assessed according to incidence, extent and severity.

时间窗: 8 weeks post surgery

次要结局

未报告次要终点

研究者

申办方类型
Industry

研究点 (5)

Loading locations...

相似试验